

## News Release

### ***Suven Pharmaceuticals Limited Revenue down by 34.05%; PAT down by 42.85% for quarter ended 31 December' 2019***

**HYDERABAD, INDIA (13 February, 2020)** – Suven Pharmaceutical Limited (SPL), a company specialized in providing pharmaceutical solutions to global life science companies, today announced its Un-audited Financial Results for the quarter and nine months ended 31st December 2019. The Un-audited Financial Results were reviewed by the audit committee and approved by the Board of Directors in their meeting held on 13th February, 2020 at Hyderabad.

Post demerger of Suven Life Sciences Limited (SLSL), the resultant entity is SPL, continuing the operations of providing pharmaceuticals solutions to global life science companies. Post approval of Honorable National Company Law Tribunal (NCLT), the financials of SPL are separated 3rd quarter onwards from Suven Life Sciences. The below financial information relating to Suven Pharmaceutical Limited only.

#### **Financial Highlights for the 3rd Quarter ended December' 2019 (QoQ):**

Income	INR 1836 Mn vs 2784 Mn - down by 34.05%
PAT	INR 514 Mn vs 899 Mn – down by 42.85%
EBIDTA	INR 849 Mn vs 1310 Mn - down by 35.16%

The Board has declared an Interim Dividend of Re.2.50 per share (250% of face value of Rs. 1.00 each) and a one-time special dividend of Rs. 2.50 per share (250% of face value of RS. 1.00 each) totaling to Rs. 5.00 per share (500% of face value of Rs. 1.00 each) post demerger of Suven's CRAMS business.

For more details please visit [www.suvenpharm.com](http://www.suvenpharm.com) and [www.suven.com](http://www.suven.com).

#### ***Risk Statement:***

*Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions contained in this news release may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive; Suven may not undertake to update any forward-looking statements that may be made from time to time.*

## **Suven Pharmaceuticals Limited**

Registered Office: # 8-2-334 | SDE Serene Chambers | 3rd Floor | Road No.5

Avenue 7 | Banjara Hills | Hyderabad – 500034 | Telangana | India | CIN:U24299TG2018PLC128171

Tel: 91 40 2354 9414 /1142 /3311 | Fax: 91 40 2354 1152 | Email: [info@suvenpharm.com](mailto:info@suvenpharm.com) | [www.suvenpharm.com](http://www.suvenpharm.com)